Thank you for subscribing!
Learn More about Next Investors - Experts in Biotech Stocks
Next Investors Archived Mar 04, 2020
Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed a commercial term sheet agreement with Farmagon, Oslo, Norway to enter the Scandinavia market with Creso products.
Next Investors Archived Mar 02, 2020
Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.
Next Investors Archived Feb 11, 2020
Creso Pharma (ASX:CPH) today announced the successful development of anibidiol®EQUI, a flavoured micromilled hemp plant product for equines and large animals.
Next Investors Archived Feb 06, 2020
Hot on the heels of major developments in human and animal health, Creso Pharma (ASX:CPH) has achieved another key milestone: a technological breakthrough that will expand its cannaQIX® human health product line,
Get expert stock analysis direct in your inbox
Next Investors Archived Jan 30, 2020
OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.
Next Investors Archived Jan 28, 2020
Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.
Next Investors Archived Jan 21, 2020
Momentum has been building over the last couple of months as CresoPharma (ASX:CPH) outlined its strategy for generating substantial growth in 2020.
Next Investors Archived Dec 19, 2019
One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).
Next Investors Archived Dec 09, 2019
Creso Pharma (ASX:CPH | FRA:1X8) has announced that through Pharma Dynamics, Creso’s partner in the African region, initial orders worth approximately A$300,000 for the cannaQIX® product range have been made.
Join Our Mailing List
